Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease
Starting soon · Not applicable
Conditions studied: Coronary Artery Disease (CAD), Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction (CMD), Vasospasm, Coronary, Stable Angina Pectoris
In brief
The goal of this clinical trial is to test whether adding coronary function testing and starting targeted medical treatment for identified vasomotor disorders will also improve angina symptoms and quality of life in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention. The main question it aims to answer is: Does performing coronary function testing in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention lead to better relieve of angina symptoms and improvement in quality of life? Researchers will compare this group undergoing coronary function testing with a control group who will solely undergo percutaneous coronary intervention. Participants will: * Undergo percutaneous coronary intervention and coronary function testing in the intervention arm * Undergo percutaneous coronary intervention in the control arm
Key facts
- Study ID
- NCT07449052
- Run by
- UMC Utrecht
- People needed
- 450
- Starts
- 2026-05-01
- Expected to finish
- 2029-03-01
- Last updated by the study team
- 2026-05-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients >18 years of age
- Hemodynamically relevant obstructive coronary artery disease (as assessed by pressure wire evaluation) in the left anterior descending coronary artery amenable to percutaneous coronary intervention at the discretion of the operator.
You may not qualify if…
- Prior coronary artery bypass graft surgery.
- Stenosis >90% in the target vessel or a stenosis deemed unsafe for pressure wire instrumentation
- Known severe left ventricular dysfunction (left ventricular ejection fraction by any imaging modality)
- Severe valvular disease
- Renal impairment (estimated glomerular filtration rate <30mL/min)
- Contra-indications for the use of adenosine or acetylcholine
- Expected inability to conform to the clinical follow-up
- Unable or unwilling to use the ORBITA-app
- Life expectancy of less than 12 months.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.